>This past spring, based on your calculations as to fully-diluted shares & market cap, you came up with a share price of 3.33 - 4.26. Any change to that?<
The post you’re referring to is #msg-19227430, from April 2007. I would say that, since then, GTC’s underlying value has increased slightly because: a) ATryn was granted Orphan Drug status by the FDA; b) GTC inked a new collaboration with ProGenetics in which GTC monetized its transgenics IP; c) Leo launched ATryn in the UK and began treating patients in the DIC trial; d) there has been modest insider buying and no insider selling; and e) GTC expects to announce a US ATryn partnership very soon.
Market Data 
Markets 
AI
